Background: Intra-articular injection of hyaluronic acid (HA) for knee osteoarthritis (OA) effectively reduces pain and delays total knee replacement (TKR) surgery; however, little is known about relative differences in clinical and cost outcomes among different HA products.
Introduction
Osteoarthritis (OA) is a common chronic illness in older adults characterized by deterioration of joint cartilage, accompanied by joint inflammation, pain, and loss of physical function. OA ranks as the fifth leading cause of disability among US adults [1] . Because age is a major risk factor for OA [2] , the prevalence of OA is expected to increase as the US population ages. In ISSN: 1740-4398 ORIGINAL RESEARCH -Relative clinical and cost outcomes among different hyaluronic acid treatments for knee osteoarthritis drugsincontext.com addition to age, previous joint injury and obesity are considered major risk factors for knee OA; previous joint injury is a common cause of knee OA among young adults [3] , whereas high body mass index (BMI) is associated with increased risk of knee OA, particularly among old adults [4] . Indeed, research shows that the annual estimated number of people in the USA with OA was approximately 30.8 million for 2008-2011 [5] . Knee OA is one of the most common forms of arthritis, with an estimated 644,000 total knee replacement (TKR) surgeries performed in 2011, 97% of which were due to osteoarthritis [6] .
Viscosupplementation, in which hyaluronic acid (HA) is injected into the knee joint for the symptomatic relief of pain, has been available for treatment of knee OA in the USA since 1997. Various mechanisms of action have been suggested to explain the clinical effects of intra-articular injection of HA (IAHA) [7] : IAHA provides extra lubrication and cushioning within affected knee joints [8] and has been shown to induce direct anti-inflammatory, chondroprotective [9] [10] [11] , and analgesic effects [12] . Hyaluronic acid injections are recognized as safe and effective for the alleviation of joint pain and improvement of joint function in patients with knee OA [13] , with positive clinical evidence demonstrated in clinical trials [14, 15] . However, after the American Academy of Orthopedic Surgeons (AAOS) revised its treatment guidelines in 2013 to issue a recommendation against the use of IAHA [16] , there has been a debate over the clinical impact of these injections. Evidence from meta-analyses has been mixed. For example, one metaanalysis showed that effects of viscosupplementation were only marginally different from placebo injections [17] , whereas another meta-analysis showed that viscosupplementation was more effective than any oral medication for knee OA pain [18, 19] . Treatment guidelines issued by different professional medical societies do not point in a single direction either. AAOS recommends against the use of IAHA, but in 2014, the American College of Rheumatology (ACR) made conditional recommendation for the use of IAHA to treat pain in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics in its position statement on viscosupplementation [20, 21] ; Osteoarthritis Research Society International (OARSI) rates the benefit of IAHA as uncertain [22] , whereas American Medical Society for Sport Medicine (AMSSM) recommends the use of IAHA for the appropriate patients with knee OA [23] .
Given such conflicting views on the clinical value of IAHA, recent research attention has turned to the real-world evidence that has been accumulating to suggest that IAHA injections result in clinical effectiveness culminating in a delay to total knee replacement [24, 25] . One study that utilized US health plan administrative claims retrospectively looked at the data of knee OA patients who ultimately underwent TKR. It showed that the HA cohort had a median 1.0-year longer time to TKR surgery than the non-HA cohort [26] ; another retrospective study with a different US health claims database has demonstrated a delay of median 1.6-year difference between the HA cohort and the non-HA cohort [27] . Populations in both studies were relatively similar in age and gender distribution; more than 70% of patients were aged 55 or older and more than 50% of patients were females. In both studies, age distributions between HA and non-HA cohorts were similar, with HA cohorts having had a slightly greater proportion of females than non-HA cohorts. When a Cox proportional hazards model (PHM) was fit to adjust for age and gender, the TKR-delaying effect of repeated HA treatments still remained.
As for the duration of knee OA, neither study provided clear information other than the time between the first diagnosis of OA and TKR, so it is uncertain whether HA and non-HA cohorts were clearly identical in disease duration at study entry. However, both studies used the first diagnosis of knee OA as the index date, implying that included patients were unlikely to be at an advanced stage of OA at study entry, and both studies also required the presence of TKR within the study window as an inclusion criterion, implying that included patients were unlikely to be at an early stage of OA at study entry due to chronic nature of knee OA. Thus, it is likely that data for both HA and non-HA cohorts were included and tracked from a relatively moderate stage of disease and thus HA and non-HA cohorts were largely comparable with each other to support valid inference with time-to-TKR analysis.
In light of these findings, additional research on the differences in clinical and cost outcomes among different HA products may be of interest to key decision makers. In the USA, various IAHA injection products, with different molecular properties, production processes, and number of injections per treatment course, are currently FDA approved for use. While a cost-effectiveness analysis of a high molecular weight, bioengineered HA with data obtained from a clinical trial [28] concluded that the HA product was less costly and more effective than conventional care with NSAID and analgesics, previous research has not examined cost and clinical effectiveness data across different HA products in the realworld setting. This study compares different US FDA-approved HA viscosupplements using real-world evidence from an administrative claims database. 
Methods

Data source
Outcome measures
The primary outcome measures were disease-specific costs associated with knee OA and time from the index date to TKR surgery. For calculation of disease-specific costs, diseasespecific claims were denoted by those claims with an OA of the knee diagnosis code while disease-specific drugs included NSAIDs, Cox-2 inhibitors, non-narcotic analgesics, opioids, and other anti-inflammatory analgesics. All index medications administered in the postindex period were considered diseasespecific whether they had an OA of the knee diagnosis or not.
Statistical analysis
Descriptive statistics were reported for continuous and categorical variables. T-tests were used for continuous variables and chi-square tests were used for categorical variables. All statistical tests were two-tailed tests. For statistical significance, we used the conventional alpha level of 0.05. A generalized linear model (GLM) with a gamma distribution and log-link 
Results
Patient characteristics
Following the application of the inclusion/exclusion criteria, a total of 50,389 patients were included for statistical analysis (Figure 1 The four different HA cohort groups were similar in baseline characteristics (Table 2) , with only relatively minor differences among them. The Euflexxa cohort had a greater proportion of patients insured through commercial health plans (61.2%) compared to the other cohorts (55.9-57.2%). In terms of physician specialty, the Orthovisc cohort had a greater proportion of patients who saw orthopedic surgeons (54.9%) compared to the other cohorts (46.3-49.2%). The four groups were similar in terms of comorbidities of interest at baseline, but for medications of interest, the Euflexxa cohort had a lower proportion of patients receiving corticosteroids (58.8%) compared to the other three cohorts (61.4-61.8%). With regards to healthcare costs, the Synvisc and Orthovisc cohorts had slightly greater preindex healthcare costs ($11,118 and $11,356) compared to the Euflexxa and Supartz/Hyalgan cohorts ($10,732 and $10,747).
Procedures of interest
The majority of patients in all four cohorts received a single course of HA treatment over the 3-year time period, ranging from 69.7% in the Synvisc cohort to 74.4% in the Supartz/ Hyalgan cohort ( 
Disease-specific healthcare costs
Comparison of the unadjusted disease-specific costs showed that the Euflexxa cohort incurred the lowest costs (mean=$13,160, median=$4,808) over the postindex period, 
Time to TKR
The Synvisc cohort had a higher proportion of patients who received TKR (26.7%) than the other three cohorts (Table 3) , which had similar rates of patients who received TKR (24.8-25.1%). The logistic regression model of incidence rates of TKR showed the Synvisc cohort had statistically significantly greater odds ratio (OR) of having a TKR than the Supartz/Hyalgan cohort (OR=1.077, p=0.0017), but there were no statistically significant differences in the ORs of having a TKR among the Euflexxa, Orthovisc, and Supartz/Hyalgan cohorts (Table 5) .
Kaplan-Meier survival curves representing proportions of subjects who had not experienced TKR across the 3-year time span were generated for the different HA cohorts (Figure 2 ). Survival curves for the Euflexxa, Orthovisc, and Supartz/ Hyalgan cohorts were similar and close together. The results of a log-rank test of survival curves suggest that Synvisc patients tended to reach TKR earlier than patients receiving other HA injections; there was a statistically significant difference between survival times of the Synvisc cohort and the Supartz/ Hyalgan cohort (p=0.0001) but no statistically significant differences among the survival times of the Euflexxa, Orthovisc, and Supartz/Hyalgan cohorts (Table 6 ). Likewise, the results of a Cox PHM for time-to-TKR (Table 7) adjusting for background covariates confirmed that the Synvisc cohort had statistically significantly greater hazard ratio (HR) of having a TKR than the Supartz/Hyalgan cohort (HR=1.069, p=0.0009), but there were no statistically significant differences in the HRs of having a TKR among the Euflexxa, Orthovisc, and Supartz/Hyalgan cohorts. The survival curve of the Synvisc cohort was statistically different from that of the Supartz/Hyalgan cohort (p=0.0001, log-rank test). 
Discussion
Real-world evidence suggests that individual HA products have clinically detectable differences in clinical and cost outcomes.
With regards to healthcare costs, in spite of the popular perception among payers that the HA products indicated for five injections per course are uneconomical, the Supartz/ Hyalgan cohort demonstrated better cost outcomes than the Synvisc and Orthovisc cohorts and similar cost outcomes of the Euflexxa cohort. This confirms the finding from an earlier study which showed that though patients in the Supartz/Hyalgan received more injections per course than patients in the Synvisc cohort, the costs to the health plan were less for the Supartz/Hyalgan cohort than for the Synvisc cohort [29] .
For the comparative effectiveness outcome of TKR delay, all HA cohorts were rather similar in their ability to delay TKR, except the Synvisc cohort which had a statistically significantly greater risk of having a TKR than the other cohorts. The statistical significance for the difference in time to TKR between the Synvisc cohort and the Supartz/Hyalgan cohort still persisted after adjustment of background covariates. This real-world finding sheds interesting light on another debate surrounding the use of IAHA regarding whether certain intrinsic properties of particular HA products such as molecular weights or production process can influence clinical outcomes [30] . Regarding molecular weight, one study suggested potential benefit of high molecular weight (HMW) HA through the CD44 receptor binding with greater affinity [31] , but another study suggested better anti-inflammatory effects of HMW HA but better chondroprotective effects of low molecular weight (LMW) HA [32] . Another study concluded that low and high molecular weight HAs were similar in efficacy and safety [33] . The current study does not show any clear relationship between molecular weight of HA and its ability to delay TKR. Regarding production process, one study showed a HA product produced by biological fermentation (Bio-HA) has a significantly smaller incidence of injection site adverse reactions than a HA product derived from avian sources (AD-HA) [34] . However, in the current study, Supartz/ Hyalgan, both of which are avian-derived hyaluronic acid (AD-HA) products, delayed TKR as effectively as other Bio-HA products, and delayed TKR longer than another AD-HA product (Synvisc). The current dataset and analyses do not provide a clear reason for this difference, but the unique chemical composition of Synvisc, which is an admixture ISSN: 1740-4398 ORIGINAL RESEARCH -Relative clinical and cost outcomes among different hyaluronic acid treatments for knee osteoarthritis drugsincontext.com of two distinctive chemically modified HAs (hylan A and hylan B) that are different from compositions of other HA products [35] , may play a part. Our findings also suggest that one may need to go beyond simple categorizations of HAs by molecular weight or production sources to account for differences in real-world clinical outcomes among HA products.
By linking the clinical outcome of delay to a major surgery and the cost outcome, the current study shows that, among the HA products considered, Euflexxa, Orthovisc, and Supartz/Hyalgan may potentially offer more value than Synvisc for payers in the US healthcare system because those HA products are more effective in delaying TKR and less costly than Synvisc. Moreover, Euflexxa and Supartz/Hyalgan may be able to achieve better cost minimization than Orthovisc given similar clinical outcomes on time to TKR. This can be valuable information to healthcare payers that need to cope with the huge economic burden that the debilitating nature and high prevalence of OA imposes on the US healthcare system. In 2009, OA resulted in approximately 921,000 hospitalizations with a mean cost per stay of $45,443, and OA-related surgeries cost the US healthcare system $42.3 billion [36] . A recent meta-analysis showed evidence that US-approved HA viscosupplements are safe and efficacious through 26 weeks in patients with knee OA and had better efficacy than non-US approved HA viscosupplements [37] . The results of this study take one further step by yielding information on the clinical and cost differences amongst various HA products that may be of interest to payers who need to shape formulary and reimbursement policies in the presence of different intra-articular HA injection products in the US healthcare market.
Limitations
As the claims data for this study is representative of the US commercially insured population, results may not be generalizable to other non-commercially insured populations such as fee-for-service Medicare, who differ with regards to demographics such as age, resource utilization, and prescription usage patterns from the commercially insured patients in our study.
This retrospective study has limitations similar to other retrospective design studies that make use of claims data, such as coding errors or omissions. Because HA products were identified via J-codes, the products that share the same J-code (Supartz and Hyalgan, Synvisc, and Synvisc-One which is identical to Synvisc in chemical composition) were analyzed together as single groups. Because the index event was defined as the initiation of HA injection treatment, a non-HA cohort was not defined in this study due to the lack of a clearly identifiable index event equivalent to the initiation of HA treatment and its stage in knee OA treatment pathway. In addition, certain systemic factors that could affect care, such as utilization management policies or plan limits on medication use, are not available in this dataset.
Because knee OA progresses slowly and it may take a long time between OA diagnosis and TKR, a long follow-up period would be ideal. However, the follow-up period in this study had to be limited to 3 years post index date due to a lack of longer follow-up data at the time of study design. In addition, direct indicators of OA disease severity including Kellgren-Lawrence scores, complete medical records of past disease duration, or patient-reported outcomes such as pain and function questionnaire scores were not available in the claims database. In their place, other demographic or clinical characteristics at baseline available within the database were used in multivariate analyses to adjust for potential differences in disease state among patients in different cohorts.
Conclusion
Analysis of the retrospective cohort data in a US health plan claims database provides real-world evidence that some intra-articular HA products may offer more value in delaying TKR than other HA products. The current finding also suggests that explanation of real-world clinical outcomes for IAHA may require considerations that go beyond simple categorization of HA by molecular weight or production process. Additional research is needed to find out more about which aspects of intrinsic HA product properties and external factors may influence clinical outcomes associated with IAHA in the realworld clinical practice. 
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